Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984073 · ClinicalTrials.gov registry record · Phase 1
Effects of Niacin On Fatty Acid Trapping
A Phase 1 study of Dyslipidemia, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT01984073: Completed Phase 1 study of Dyslipidemia, sponsored by University of Pennsylvania.
NCT01984073 is a Phase 1 study of Dyslipidemia that has completed, run by University of Pennsylvania. The registered enrollment target is 26 participants, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01984073, a Phase 1 study of Dyslipidemia, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand whether a vitamin called NIcotinic ACid vitamIN (NIACIN for short, also known as vitamin B3) helps the body process dietary fat more efficiently. This is important because people with dyslipidemia have a problem with how they process fat, which raise the risk of heart disease.
Primary Outcome
Plasma Triglycerides (TGs) after oral fat challenge will be measured to assess post-prandial lipidemia after niacin and placebo. Parameters of interest are the area under the curve (AUC), time to peak (t-max), and peak concentration (c-max). The relevant units will be mg.h/dl for plasma triglyceride AUC, minutes for time to peak plasma TG and mg/dl for c-max.
Conditions Studied
Interventions
- DRUG ER Niacin Oral Fat Challenge
- DRUG IR Niacin Oral Fat Challenge
- OTHER Placebo Oral Fat Challenge
Study Locations (2)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Presbyterian Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-12 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
What the finished NCT01984073 record still lists
NCT01984073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 3 interventions - of which ER Niacin Oral Fat Challenge is the first listed.
NCT01984073 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01984073 about?
NCT01984073 is a clinical study titled "Effects of Niacin On Fatty Acid Trapping". The purpose of this study is to understand whether a vitamin called NIcotinic ACid vitamIN (NIACIN for short, also known as vitamin B3) helps the body process dietary fat more efficiently. This is important because people with dyslipidemia have a problem with how they process fat, which raise the ri...
What is the current status of trial NCT01984073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-12. Estimated completion is 2019-12.
What conditions does trial NCT01984073 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT01984073?
The interventions under investigation include: ER Niacin Oral Fat Challenge (DRUG), IR Niacin Oral Fat Challenge (DRUG), Placebo Oral Fat Challenge (OTHER).
Who is sponsoring clinical trial NCT01984073?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01984073 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01984073's enrollment target sits among peer trials
26 34th of 40 higher than 7 of 40 other Dyslipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
RECRUITING · Phase 1
-
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
COMPLETED · Phase 1
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
COMPLETED · Phase 1
-
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
COMPLETED · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia